** Shares of drug developer Cargo Therapeutics CRGX.O fall 77.4% to record low of $2.99
** On Wednesday, CRGX said it is stopping a mid-stage trial for cancer treatment
** Trial was stopped due to serious side effects in some patients, including a severe inflammatory condition - CRGX
** CRGX has $368.1 million in cash and expects it to last until mid-2028
** CRGX also said it is reducing its workforce by about 50%
** As of Sept. 30, 2024, co had 170 full-time employees - SEC filing
** CRGX fell 36.5% in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。